Antifungal agents - PowerPoint PPT Presentation

1 / 22
About This Presentation
Title:

Antifungal agents

Description:

Antifungal agents Pawitra Pulbutr M.Sc. In Pharm (Pharmacology) ... – PowerPoint PPT presentation

Number of Views:702
Avg rating:3.0/5.0
Slides: 23
Provided by: elearnin6
Category:

less

Transcript and Presenter's Notes

Title: Antifungal agents


1
Antifungal agents
  • Pawitra Pulbutr
  • M.Sc. In Pharm (Pharmacology)

2
????????????????????????
  • ?????????????????????????????????, ?????????,
    ??????????????, ??????????????????????????????????
    ??, ???????????????????????????
    ??????????????????????????????????????

3
Antifungal agents
  • Systemic antifungal for systemic infection
  • Systemic antifungal for mucocutaneous infection
  • Topical antifungal agents

4
Systemic antifungal for systemic infection
  • Amphotericin B
  • Flucytosine (5-FC)
  • Azoles
  • Ketoconazole
  • Itraconazole
  • Fluconazole
  • Voriconazole

5
Amphotericin B Mechanism of action
  • Cell membrane binding
  • Target Ergosterol of fungal cell membrane
  • Pore forming action
  • Increase cell membrane permeability
  • Selective fungicidal
  • Resistance
  • Decrease ergosterol binding
  • decrease ergosterol number
  • decrease ergosterol affinity

6
  • Most broadest spectrum
  • Candida albicans
  • Cryptococcus neoformans
  • Histoplasma capsulatum
  • Blastomyces dermatitidis
  • Coccidioides immitis
  • Aspergillus fumigatus
  • Paracoccidioides brasilliensis
  • Penicillium maeneffei
  • Mucormycosis (Rhizopus, Rhizomucor,
    Cunninghamella)
  • Not to Candida lusitaniae, Pseudallescheria
    boydii

Antifungal activity
7
ADRs
  • Immediate reaction
  • Infusion related toxicity
  • Fever, chills, muscle spasms, vomiting,
    headache, hypotension
  • Slower infusion
  • Premedication with ibuprofen, paracetamol,
    diphenhydramine, hydrocortisone

8
ADRs
  • Slower reaction
  • Drug toxicity
  • Renal damage
  • decrease renal perfusion, prerenal failure
    reversible
  • renal tubular injury, tubular dysfunction
    irreversible
  • renal tubular acidosis, severe Mg K wasting
    gtgtgt hypokalemia
  • Sodium loading gtgtgt decrease prerenal toxic

9
Amphotericin B formulation
  • Conventional
  • Amphotericin B desoxycholate (DOC)
  • Lipid formulation
  • Amphotericin B Colloidal Dispersion (ABCD)
  • Amphotericin B Lipid complex (ABLC)
  • Small unilamellar vesicle formulation of
    amphotericin B (AmBisome)

Less bind to mammalian cells Less
nephrotoxicity Expensive
10
Flucytosine (5-FC)
  • water soluble pyrimidine analog
  • 5-FU like structure
  • Well GI absorption gt 90
  • Well distribution including CSF
  • Renal excretion glomerular filtration
  • Mechanism of action
  • Uptake into fungi by cytosine permease
  • Converted into 5-FU converted to
  • 5-fluorodeoxyuridine monophosphate (F-dUMP)
    inhibit DNA synthesis
  • 5-fluorouridine triphosphate inh. RNA syn.

11
Azole compounds
  • Imidazole
  • ketoconazole
  • miconazole
  • clotrimazole
  • Triazole
  • itraconazole
  • fluconazole
  • voriconazole

12
Mechanism of action
  • Inhibit fungal CYP 450
  • sterol 14 a demethylase
  • Inhibit ergosterol synthesis
  • Imidazole less specific to fungal enzyme
  • Imidazole may inhibit human enzyme
  • Drug interaction Enzyme inhibitor
  • ADRs Inhibit steroid hormone synthesis

13
Clinical uses
  • Broad spectrum
  • Candiasis
  • Cryptococcosis
  • Blastomycosis
  • Histoplasmosis
  • Dermatophytosis ringworm
  • Pseudallescheria boydii infection
  • Aspergillosis
  • Sporothricosis

14
Systemic drug for mucocutaneous infection
  • Griseofulvin
  • Terbinafine

15
Griseofulvin
  • Unclear mechanism of action fungistatic
  • inhibit mitotic spindle function Inhibit
    fungal mitosis
  • Accumulation in keratin
  • New skin Non-infected
  • Oral well absorption with fatty meal
  • Skin/ Nail/ Hair fungal infection
  • Late onset 2-6 week
  • Microsized Ultramicrosized preparation

16
Terbinafine (Lamisil)
  • Synthetic allyamine well oral absorption
    extensive first pass metabolism
  • Mechanism Inhibit ergosterol synthesis
  • Inhibit fungal squalene epoxidase
  • Accumulation of toxic sterol squalene
  • Fungicidal Keratophilic
  • Clinical uses
  • Dermatophytes
  • Onychomycosis
  • 250 mg/ day 6 weeks (finger) or 12 weeks (toe)

17
Topical antifungal therapy
  • Superficial Cutaneous fungal infection
  • Stratum corneum, Squamous mucosa, Cornea
  • Dermatophytosis (ring worm)
  • Cutaneous candidiasis
  • Tinea vesicolor, Piedra
  • Fungal keratitis
  • Not effective for onychomycosis, tinea capitis
    (head), subcutaneous mycosis

18
Nystatin
  • Polyene macrolide
  • Pore forming at cell membrane
  • Amphotericin B like mechanism
  • Topical only for candidiasis only
  • Non GI, mucus absorption
  • Clinical uses local candida infection
  • Oral suspension / Vaginal tablet
  • Oral thrush (swish swallow), Vaginal
    candidiasis, Intertriginous candidal infection

New York State Health Lab
19
Topical Azole
  • Clotrimazole
  • Miconazole
  • Econazole
  • Isoconazole
  • Ketoconazole
  • Tinea corporis, Tinea pedis, Tinea crusis
  • Vaginal candidiasis, Oral thrush, Cutaneous
    candidiasis
  • Seborrheic dermatitis
  • Pityriasis vesicolor
  • Cutaneous application
  • Vaginal suppository (Clotrimazole)
  • Oral troches

20
Topical allylamine
  • Terbinafine
  • Naftifine
  • Tinea crusis, Tinea corposis, Tinea pedis
  • Less effective to Candida, tinea vesicolor
  • Irritation

21
  • Systemic antifungal for systemic infection
  • Amphotericin B
  • 5-FC
  • Azole .. Ketoconazole, itraconazole,
    fluconazole, voriconazole
  • Systemic antifungal for mucocutaneous infection
  • Griseofulvin
  • Terbinafine
  • Topical antifungal agents
  • Nystatin
  • Topical azole
  • Topical allylamine
  • Miscellaneous

22
THE END
Write a Comment
User Comments (0)
About PowerShow.com